Table 2.

Dose reduction criteria for carboplatin and pemetrexed

Platelet (/L)	Neutrophil (/mm3)	CBDCA	PEM
Haematological adverse events
≥50×109	≥500	No reduction	No reduction
≥50×109	<500	1 dose down	1 dose down
<50×109 without bleeding	Any	1 dose down	1 dose down
<50×109 with bleeding	Any	2 dose down	2 dose down
Any	<1000 and fever (≥38.5°C)	2 dose down	1 dose down
Non-haematological adverse events
Nausea, vomit, appetite loss	Grade 4	1 dose down	1 dose down
Diarrhoea	Grade 3 or 4	No reduction	1 dose down
Enanthema	Grade 3 or 4	No reduction	2 dose down
Neurological toxicity	Grade 3 or 4	1 dose down	1 dose down
AST/ALT	Grade 3	1 dose down	1 dose down
	Grade 4	Discontinue	Discontinue
Others	Grade 4	1 dose down	1 dose down

ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CBDCA, carboplatin; PEM, pemetrexed.